John J. Miller, MD

Learn more about the history of pharmacogenomics.

Why DSM diagnoses shape treatment and insurance denials—and how a WHO-aligned, dimension-based system could modernize psychiatry beyond DSM-5-TR.

Explore how glutamate and GABA balance brain excitation and inhibition, shaping development, learning, and disorders like depression, schizophrenia, and autism.

APA shares DSM recommendations, and John J. Miller, MD, reviews and weighs in.

How ketamine sparks a glutamate-driven BDNF burst, reshaping prefrontal connectivity in depression and revealing the glutamate–GABA partnership.

John J. Miller, MD, weighs in on APA's plans for the DSM and why global integration with the ICD should shape psychiatry’s future.

In response to the APA’s roadmap for the future DSM, John J. Miller, MD, examines how its rigid diagnostic categories may limit clinicians’ ability to deliver care.

John Miller, MD, discusses the APA's new publications on the future of the DSM, highlighting key domains for mental health diagnosis and treatment.

In this CME article, explore the groundbreaking role of muscarinic cholinergic receptors in schizophrenia treatment, highlighting innovative therapies like KarXT for improved patient outcomes.

Psychiatric Times is excited to embrace change with new digital editions and engaging content, and invite you, our readers, to explore diverse topics across multiple platforms.

Explore the complexities of pharmacogenetic testing in psychiatry, uncovering its current limitations and future potential in personalized medicine.

Explore the complexities of delirium and its neuropsychiatric disturbances, highlighting innovative treatment approaches and the latest research insights.

Psychiatric Times celebrates 40 years of impactful insights, exploring key topics in psychiatry, including medication management and emerging treatments.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

Explore the profound impact of mentorship in medicine, highlighting personal journeys and the legacy of influential mentors like Wassfy Hanna, MD.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

Debate over using SSRIs in pregnancy in recent FDA focus group raises questions, despite extensive research supporting SSRI use for maternal mental health.

A trio of practitioners react to the FDA advisory committee's 10-1 vote against recommending approval of brexpiprazole (Rexulti) adjunctive to sertraline for adults with PTSD.

Learn more about how serum drug levels enhance psychiatric treatment by providing critical insights into medication efficacy and patient outcomes.

Learn more about how to best assess and treat tardive dyskinesia.

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

John J. Miller, MD, discusses the updates to the delirium practice guidelines with Mark A. Oldham, MD

The therapeutic alliance in psychiatry: enhancing patient engagement and treatment outcomes through effective communication and collaboration.